Compare Eli Lilly And Co (LLY) vs S&P Global Inc (SPGI) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

S&P Global (SPGI) trades at $449.75, down 0.24% on the day, with a bullish technical outlook and strong fundamentals. The stock shows robust profitability with a 30.36% net income margin and consistent revenue growth, reaching $15.34B in 2025. Recent corporate actions include the spinoff of Mobility Global, streamlining operations. Analyst consensus is strongly bullish with a $531.11 price target, and technical indicators signal a buy from moving averages despite overbought RSI levels.

The outlook for SPGI is positive, driven by margin expansion targets, AI-driven growth in API usage, and resilient recurring revenues. Key risks include high valuation multiples and sensitivity to debt issuance cycles. Investment opportunity lies in its market-leading position and strategic focus post-spinoff, though investors should monitor execution on growth initiatives and macroeconomic factors affecting capital markets.